Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2’ site

• Sabrina Lusvarghi ,

  Contributed equally to this work with: Sabrina Lusvarghi, Russell Vassell

  Roles Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing

  Affiliation Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Russell Vassell ,

  Contributed equally to this work with: Sabrina Lusvarghi, Russell Vassell

  Roles Conceptualization, Formal analysis, Investigation, Methodology, Writing – review & editing

  Affiliation Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Brittany Williams,

  Roles Investigation, Writing – review & editing

  Affiliation Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Haseebullah Baha,

  Roles Investigation, Writing – review & editing

  Affiliation Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Sabari Nath Neerukonda,

  Roles Methodology, Writing – review & editing

  Affiliation Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Carol D. Weiss

  Roles Conceptualization, Formal analysis, Funding acquisition, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing

  * E-mail: carol.weiss@fda.hhs.gov

  Affiliation Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  https://orcid.org/0000-0002-9965-1289

  ⨯